Fintel reports that on April 15, 2025, Baird downgraded their outlook for Elevance Health (NYSE:ELV) from Outperform to ...

FDA-cleared CureSight™ therapy now reimbursed by Elevance Health, expanding access to effective digital treatment for lazy ...

Strive Health, the national leader in value-based kidney care, announced today that it has expanded its executive team.

Glen Tullman, the CEO of Transcarent, is taking another big shot at transforming the U.S. health care system.

Why it matters: The mixed results from two of the nation’s top Medicare Advantage insurers highlight the uncertainty facing ...

A total of 8 analyst ratings have been received for Elevance Health, with the consensus rating being Outperform. The average ...

We recently published a list of 10 Best Telehealth Stocks to Buy Now. In this article, we are going to take a look at where ...

For full-year 2024, Elevance reported $175.2 billion in revenue, an increase of 2.9% over its $170.2 billion haul in 2023.

High Medicare Advantage spending continues to dog major carriers such as Elevance Health and UnitedHealth Group.

Truist Financial analyst Jailendra Singh reiterated a Buy rating on Elevance Health (ELV – Research Report) today. The company’s shares closed ...